menu
    • menu
    [{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Antibody drug conjugate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Sanyou Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BC008","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Sanyou Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Sanyou Biopharmaceuticals \/ Sanyou Biopharmaceuticals"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Dragon Sail Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Biological Product","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Sinorda Biomedicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine","highestDevelopmentStatusID":"4","companyTruncated":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sanyou Biopharmaceuticals

    Menu

    Sanyou Biopharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Hangzhou Zhongmei Huadong Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials

                            Details : The collaboration aims to advance the development of SYHD001, as an ADC drug, which is being evaluated in the early-stage clinical trial studies for the treatment of neoplasms.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Hangzhou Zhongmei Huadong Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bispecific Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Sinorda Biomedicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sanyou Biopharmaceuticals and Sinorda Biomedicine Signed Strategic Cooperation Agreement for Advancing Innovat...

                            Details : The agreement aims to advance the innovative bispecific antibody drug project by leveraging Sanyou's world-leading core technology platform for integrated R&D and preclinical development and Sinorda's rich experience in preclinical and clinical oncology ...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 22, 2023

                            Lead Product(s) : Bispecific Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Sinorda Biomedicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Biological Product

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Hangzhou Zhongmei Huadong Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sanyou Forms Partnership with Hangzhou Zhongmei Huadong Pharmaceutical, Catalyzing Innovative Drug Research an...

                            Details : Under the agreement, the companies will develop therapeutic biological products in the therapeutic area of oncology through Sanyou's world-leading core technology platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 28, 2023

                            Lead Product(s) : Biological Product

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Hangzhou Zhongmei Huadong Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Dragon Sail Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Sanyou Biopharmaceuticals Forged Strategic Partnership with Dragon Sail Pharmaceutical to Upgrade Integrated I...

                            Details : Sanyou will provide preclinical R&D services including drug screening, pharmacology research, process development and quality control of various biological drugs including monoclonal antibodies, multi-specific antibodies, ADC drugs, etc.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 20, 2022

                            Lead Product(s) : Antibody

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Dragon Sail Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC008

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Dragon Boat Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sanyou Bio Congratulates Dragon Boat Pharmaceutical on the Approval of Clinical Trials of anti-CLDN18.2 Antibo...

                            Details : Preclinical study data of BC008 antibody injection showed drug can specifically target and bind CLDN18.2 molecules on cell surface, and play an anti-tumor role by specifically killing CLDN18.2-positive tumor cells through Fc-mediated immune effector func...

                            Brand Name : BC008

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 20, 2022

                            Lead Product(s) : BC008

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Dragon Boat Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sanyou Biopharmaceuticals

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody drug conjugate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Shanghai Henlius Biotech

                            Deal Size : $3.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Shanghai Henlius Biotech Says Entered Cooperation Agreement With Sanyou Biopharmaceuticals & Shanghai Zj Bio-T...

                            Details : Agreement aims to develop fully human antibody drug for covid-19 for monotherapy or combination treatment of covid-19.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 06, 2020

                            Lead Product(s) : Antibody drug conjugate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Shanghai Henlius Biotech

                            Deal Size : $3.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth